» Articles » PMID: 36677054

The Implication of Mechanistic Approaches and the Role of the Microbiome in Polycystic Ovary Syndrome (PCOS): A Review

Abstract

As a complex endocrine and metabolic condition, polycystic ovarian syndrome (PCOS) affects women's reproductive health. These common symptoms include hirsutism, hyperandrogenism, ovulatory dysfunction, irregular menstruation, and infertility. No one knows what causes it or how to stop it yet. Alterations in gut microbiota composition and disruptions in secondary bile acid production appear to play a causative role in developing PCOS. PCOS pathophysiology and phenotypes are tightly related to both enteric and vaginal bacteria. Patients with PCOS exhibit changed microbiome compositions and decreased microbial diversity. Intestinal microorganisms also alter PCOS patient phenotypes by upregulating or downregulating hormone release, gut-brain mediators, and metabolite synthesis. The human body's gut microbiota, also known as the "second genome," can interact with the environment to improve metabolic and immunological function. Inflammation is connected to PCOS and may be caused by dysbiosis in the gut microbiome. This review sheds light on the recently discovered connections between gut microbiota and insulin resistance (IR) and the potential mechanisms of PCOS. This study also describes metabolomic studies to obtain a clear view of PCOS and ways to tackle it.

Citing Articles

Reliability of noninvasive hyperspectral tongue diagnosis for menstrual diseases using machine learning method.

Liang A, Ge J, Liu Z, Han X, Hou S, Li G Sci Rep. 2025; 15(1):6138.

PMID: 39979510 PMC: 11842557. DOI: 10.1038/s41598-025-90679-9.


The role of immunity in insulin resistance in patients with polycystic ovary syndrome.

Zhang Q, Yang Z, Ou X, Zhang M, Qin X, Wu G Front Endocrinol (Lausanne). 2025; 15:1464561.

PMID: 39911236 PMC: 11797073. DOI: 10.3389/fendo.2024.1464561.


Modulatory impact of subsp. BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection.

Dong Y, Yang S, Zhang S, Zhao Y, Li X, Han M mSphere. 2025; 10(2):e0088724.

PMID: 39898662 PMC: 11853005. DOI: 10.1128/msphere.00887-24.


Hotspots and research trends of gut microbiome in polycystic ovary syndrome: a bibliometric analysis (2012-2023).

Wu R, Mai Z, Song X, Zhao W Front Microbiol. 2025; 15():1524521.

PMID: 39845049 PMC: 11753182. DOI: 10.3389/fmicb.2024.1524521.


Curcumin mitigates polycystic ovary syndrome in mice by suppressing TLR4/MyD88/NF-κB signaling pathway activation and reducing intestinal mucosal permeability.

Yang Q, Wan Q, Wang Z Sci Rep. 2024; 14(1):29848.

PMID: 39617843 PMC: 11609283. DOI: 10.1038/s41598-024-81034-5.


References
1.
Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y . Association between Polycystic Ovary Syndrome and Gut Microbiota. PLoS One. 2016; 11(4):e0153196. PMC: 4836746. DOI: 10.1371/journal.pone.0153196. View

2.
Genazzani A, Ricchieri F, Lanzoni C . Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond). 2010; 6(4):577-93. DOI: 10.2217/whe.10.43. View

3.
Zhang T, Chi X . Estrogenic properties of genistein acting on FSHR and LHR in rats with PCOS. Pol J Vet Sci. 2019; 22(1):83-90. DOI: 10.24425/pjvs.2019.127075. View

4.
Elci E, Kaya C, Cim N, Yildizhan R, Gunes Elci G . Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. Gynecol Endocrinol. 2016; 33(1):43-47. DOI: 10.1080/09513590.2016.1203893. View

5.
Zhang J, Hu J, Zhang C, Jiao Y, Kong X, Wang W . Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease. Exp Ther Med. 2018; 15(5):4259-4264. PMC: 5920378. DOI: 10.3892/etm.2018.5932. View